DTIL Stock Price, Precision BioSciences Quote, Chart

Market Summary

USD12.35+0.37

Delayed

3.09%

DTIL Stock Price

View Fullscreen

DTIL RSI Chart

DTIL Valuation

Market Cap

85.5M

Price/Earnings (Trailing)

-3.09

Price/Sales (Trailing)

1.49

Price/Free Cashflow

-1.19

DTIL Price/Sales (Trailing)

DTIL Profitability

Return on Equity

-74.37%

Return on Assets

-14.98%

Free Cashflow Yield

-83.75%

DTIL Fundamentals

DTIL Revenue

Revenue (TTM)

57.5M

Rev. Growth (Yr)

100.27%

Rev. Growth (Qtr)

149.84%

DTIL Earnings

Earnings (TTM)

-27.7M

Earnings Growth (Yr)

134.27%

Earnings Growth (Qtr)

152.72%

Breaking Down DTIL Revenue

Last 7 days

16.1%

Last 30 days

7.3%

Last 90 days

4.2%

Trailing 12 Months

-43.6%

How does DTIL drawdown profile look like?

DTIL Financial Health

Current Ratio

4.82

Debt/Equity

0.6

Debt/Cashflow

-3.22

DTIL Investor Care

Shares Dilution (1Y)

82.58%

Diluted EPS (TTM)

-7.36

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	57.5M	0	0	0
2023	30.6M	46.5M	52.3M	48.7M
2022	102.5M	37.5M	20.8M	25.1M
2021	33.6M	101.4M	118.0M	115.5M
2020	23.8M	19.5M	22.0M	24.3M
2019	14.8M	18.3M	20.7M	22.2M
2018	0	0	0	10.9M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Precision BioSciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 08, 2024	kelly john alexander	acquired	100,008	12.00	8,334	chief financial officer
May 08, 2024	smith j. jefferson	acquired	9,996	12.00	833	chief research officer
May 08, 2024	amoroso michael	acquired	100,008	12.00	8,334	president and ceo
May 08, 2024	scimeca dario	acquired	9,996	12.00	833	general counsel and secretary
May 04, 2024	brown melinda	acquired	-	-	4,202	-
May 04, 2024	wadsworth samuel c.	acquired	-	-	4,202	-
May 04, 2024	frankel stanley	acquired	-	-	4,202	-
May 04, 2024	buehler kevin	acquired	-	-	4,202	-
May 04, 2024	germano geno j	acquired	-	-	4,202	-
May 04, 2024	pire shari lisa	acquired	-	-	4,202	-

Which funds bought or sold DTIL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	BARCLAYS PLC	sold off	-100	-78,000	-	-%
May 15, 2024	Aquilo Capital Management, LLC	new	-	5,226,570	5,226,570	3.92%
May 15, 2024	Tower Research Capital LLC (TRC)	new	-	5,275	5,275	-%
May 15, 2024	Alyeska Investment Group, L.P.	new	-	3,390,000	3,390,000	0.02%
May 15, 2024	AMUNDI	sold off	-100	-112,020	-	-%
May 15, 2024	Blue Owl Capital Holdings LP	new	-	274,183	274,183	0.06%
May 15, 2024	STATE STREET CORP	sold off	-100	-89,187	-	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	new	-	385,280	385,280	-%
May 15, 2024	MORGAN STANLEY	new	-	159,452	159,452	-%
May 15, 2024	Royal Bank of Canada	new	-	-	-	-%

Are Funds Buying or Selling DTIL?

Are funds buying DTIL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own DTIL

No. of Funds

Unveiling Precision BioSciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 18, 2024	aquilo capital management, llc	7.1%	466,767	SC 13G
Mar 14, 2024	perceptive advisors llc	7.9%	5e+05	SC 13G
Mar 11, 2024	janus henderson group plc	8.0%	511,108	SC 13G
Feb 14, 2024	great point partners llc	0%	0	SC 13G/A
Feb 09, 2024	capital world investors	4.2%	5,119,458	SC 13G/A
Feb 05, 2024	tang capital partners lp	5.2%	6,400,000	SC 13G
Feb 27, 2023	great point partners llc	7.30%	8,099,799	SC 13G
Feb 14, 2023	great point partners llc	3.43%	3,801,305	SC 13G/A
Feb 13, 2023	capital world investors	6.1%	6,715,043	SC 13G/A
Feb 09, 2023	vanguard group inc	3.94%	4,373,367	SC 13G/A

Recent SEC filings of Precision BioSciences Inc

View All Filings

Date Filed	Form Type	Document
May 13, 2024	10-Q	Quarterly Report
May 13, 2024	8-K	Current Report
May 08, 2024	4	Insider Trading
May 08, 2024	4	Insider Trading
May 08, 2024	4	Insider Trading
May 08, 2024	4	Insider Trading
May 08, 2024	8-K	Current Report
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading

Peers (Alternatives to Precision BioSciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Precision BioSciences Inc News

Latest updates

Precision BioSciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	149.8%	17,584	7,038	13,120	19,789	8,780	10,598	7,363	3,820	3,317	6,339	24,036	68,805	16,349	8,846	7,363	1,078	6,998	6,522	4,865	5,389	5,462
Operating Expenses	82.3%	21,771	11,944	25,483	31,776	33,244	12,024	22,039	33,374	30,652	37,063	35,578	47,173	35,091	32,326	33,407	33,886	34,494	28,383	26,843	29,260	24,956
S&GA Expenses	-100.0%	-	8,539	9,633	9,830	11,086	9,955	10,281	10,438	10,680	10,593	9,638	9,938	9,498	9,200	8,534	8,703	9,615	8,479	7,052	6,500	4,995
R&D Expenses	291.9%	13,343	3,405	15,850	21,946	22,158	2,070	11,758	22,936	19,972	26,470	25,940	37,235	25,593	23,126	24,873	25,183	24,879	19,904	19,791	22,760	19,961
Interest Expenses	-0.9%	574	579	576	553	522	486	405	178	42.00	53.00	55.00	24.00	-	-	-	-	-	-	-	-	182
Net Income	152.7%	8,588	-16,289	-8,079	-11,891	-25,060	-28,488	-23,946	-31,035	-28,168	-22,290	-11,279	21,656	-18,689	-23,453	-26,016	-32,701	-26,836	-20,916	-20,742	-19,436	-31,783
Net Income Margin	61.8%	-0.48*	-1.26*	-1.41*	-1.92*	-3.55*	-4.45*	-5.06*	-2.47*	-0.39*	-0.26*	-0.27*	-0.46*	-	-	-	-	-	-	-	-	-
Free Cashflow	-125.3%	-18,981	-8,423	-23,093	-21,134	-31,464	-21,843	29,186	-24,224	-28,872	-23,681	-23,905	-31,339	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	15.6%	185	160	164	182	205	238	272	297	181	211	227	230	262	150	169	184	214	235	260	272	167
Current Assets	17.9%	161	136	146	148	169	199	225	248	134	162	183	188	219	106	123	137	167	194	220	237	137
Cash Equivalents	18.1%	138	117	122	138	158	190	212	184	116	144	160	174	193	90.00	104	127	154	181	206	226	116
Net PPE	-16.6%	5.00	6.00	9.00	18.00	19.00	12.00	22.00	23.00	24.00	25.00	32.00	33.00	34.00	35.00	36.00	38.00	39.00	40.00	39.00	33.00	28.00
Liabilities	4.7%	148	141	135	148	164	178	187	194	112	120	126	130	203	106	105	99.00	99.00	97.00	105	98.00	156
Current Liabilities	-33.3%	33.00	50.00	51.00	56.00	47.00	60.00	61.00	54.00	29.00	36.00	36.00	36.00	64.00	43.00	42.00	34.00	24.00	27.00	24.00	16.00	71.00
Long Term Debt	-	-	-	-	-	22.00	22.00	22.00	22.00	2.00	2.00	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	97.3%	37.00	19.00	29.00	34.00	40.00	60.00	84.00	103	70.00	91.00	101	101	59.00	44.00	64.00	86.00	115	138	156	174	11.00
Retained Earnings	1.8%	-481	-489	-473	-465	-453	-428	-399	-375	-344	-316	-294	-283	-304	-286	-262	-236	-203	-177	-156	-135	-115
Additional Paid-In Capital	1.9%	519	509	503	500	495	490	485	480	415	409	397	385	365	331	327	323	320	316	313	310	128
Shares Outstanding	66.1%	7.00	4.00	4.00	4.00	4.00	4.00	4.00	2.00	2.00	2.00	2.00	2.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	59.00	-	-	-	170	-	-	-	664	-	-	-	383	-	-	-	589	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-125.3%	-18,981	-8,423	-23,093	-21,134	-31,464	-21,843	29,186	-24,224	-28,872	-23,681	-23,905	-31,339	68,072	-13,452	-22,223	-25,801	-25,910	-20,556	-13,977	-16,575	-19,907
Share Based Compensation	-2.1%	2,906	2,969	3,105	3,874	4,092	4,536	5,133	5,138	4,390	4,435	4,551	3,896	3,632	3,854	3,709	3,118	3,105	2,621	2,491	2,279	1,549
Cashflow From Investing	-161.9%	-26.00	42.00	7,564	-1,056	-721	-632	-1,090	-779	-818	-1,505	-1,483	-1,690	-1,125	-1,096	-1,047	-1,785	-1,103	-5,529	-5,918	-8,137	-5,082
Cashflow From Financing	1317.8%	40,095	2,828	-34.00	1,852	741	-	-180	92,916	2,249	8,378	11,916	13,512	36,715	198	532	285	314	706	61.00	134,312	38,295

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

DTIL Income Statement

2024-03-31

CONDENSED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue	$ 17,584	$ 8,780
Operating expenses
Research and development	13,343	11,048
General and administrative	8,428	11,086
Total operating expenses	21,771	22,134
Operating loss	(4,187)	(13,354)
Other income (expense):
Gain (loss) from equity method investment	1,713	(1,341)
Loss on changes in fair value	(348)	(769)
Gain on change in fair value of warrant liability	10,386
Interest expense	(574)	(522)
Interest income	1,663	2,043
Loss on disposal of assets	(65)	(7)
Total other income (expense)	12,775	(596)
Income (loss) from continuing operations	8,588	(13,950)
Loss from discontinued operations		(11,110)
Net income (loss)	$ 8,588	$ (25,060)
Net income (loss) per share - Basic	$ 1.7	$ (6.75)
Net income (loss) per share - Diluted	$ 1.7	$ (6.75)
Weighted average common shares outstanding - Basic	5,060,978	3,709,894
Weighted average common shares outstanding - Diluted	5,063,406	3,709,894

DTIL Balance Sheet

2024-03-31

CONDENSED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 137,766	$ 116,678
Accounts receivable	390	901
Prepaid expenses	9,254	5,977
Convertible note receivable	11,553	11,897
Assets held for sale	378	487
Contract asset	1,359
Other current assets	128	419
Total current assets	160,828	136,359
Property, equipment, and software—net	5,286	6,338
Intangible assets—net	386	400
Right-of-use assets—net	7,979	8,263
Investment in equity securities	3,206	3,206
Note receivable—net	6,818	4,990
Other assets	238	225
Total assets	184,741	159,781
Current liabilities:
Accounts payable	1,136	2,968
Accrued compensation	1,220	4,978
Accrued research and development expenses	656	1,557
Deferred revenue	2,406	12,035
Loan payable-net	22,460	22,412
Lease liabilities	1,182	1,133
Other current liabilities	2,772	2,391
Current liabilities of discontinued operations	1,506	2,513
Total current liabilities	33,338	49,987
Deferred revenue	74,766	73,082
Lease liabilities	7,411	7,723
Warrant liability	22,020
Contract liabilities	10,000	10,000
Noncurrent liabilities of discontinued operations		128
Total liabilities	147,535	140,920
Commitments and contingencies (Note 4)
Stockholders’ equity:
Preferred stock, $0.0001 par value- 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023; no shares issued and outstanding as of March 31, 2024 and December 31, 2023
Common stock; $0.000005 par value - 200,000,000 shares authorized as of March 31, 2024 and December 31,2023; 6,943,254 shares issued and 6,916,239 shares outstanding as of March 31, 2024; 4,191,053 shares issued and 4,164,038 shares outstanding as of December 31, 2023	1	1
Additional paid-in capital	519,200	509,443
Accumulated deficit	(481,043)	(489,631)
Treasury stock	(952)	(952)
Total stockholders’ equity	37,206	18,861
Total liabilities and stockholders’ equity	$ 184,741	$ 159,781

About Precision BioSciences Inc

Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders. It also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, an azercabtagene zapreleucel, for the treatment of acute lymphoblastic leukemia and B-cell precursor acute lymphoblastic leukemia; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T cell candidate targeting B-cell maturation antigen for relapsed or refractory (R/R) multiple myeloma in combination with nirogacestat, a gamma secretase inhibitor. The company has development and commercial license agreements with Les Laboratoires Servier to develop allogeneic CAR T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

CEO	Mr. Michael Amoroso
WEBSITE	precisionbiosciences.com
INDUSTRY	Biotechnology
EMPLOYEES	192

Precision BioSciences Inc Frequently Asked Questions

What is the ticker symbol for Precision BioSciences Inc? What does DTIL stand for in stocks?

DTIL is the stock ticker symbol of Precision BioSciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Precision BioSciences Inc (DTIL)?

As of Fri May 17 2024, market cap of Precision BioSciences Inc is 85.53 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DTIL stock?

You can check DTIL's fair value in chart for subscribers.

What is the fair value of DTIL stock?

You can check DTIL's fair value in chart for subscribers. The fair value of Precision BioSciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Precision BioSciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DTIL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Precision BioSciences Inc a good stock to buy?

The fair value guage provides a quick view whether DTIL is over valued or under valued. Whether Precision BioSciences Inc is cheap or expensive depends on the assumptions which impact Precision BioSciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DTIL.

What is Precision BioSciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, DTIL's PE ratio (Price to Earnings) is -3.09 and Price to Sales (PS) ratio is 1.49. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DTIL PE ratio will change depending on the future growth rate expectations of investors.